Compare PBT & BIOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PBT | BIOA |
|---|---|---|
| Founded | 1980 | 2015 |
| Country | United States | United States |
| Employees | N/A | 62 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 776.6M |
| IPO Year | N/A | N/A |
| Metric | PBT | BIOA |
|---|---|---|
| Price | $21.37 | $16.53 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $51.50 |
| AVG Volume (30 Days) | 153.9K | ★ 414.5K |
| Earning Date | 03-13-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.51% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $846.41 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $57.37 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.37 | $3.66 |
| 52 Week High | $22.71 | $24.00 |
| Indicator | PBT | BIOA |
|---|---|---|
| Relative Strength Index (RSI) | 50.94 | 41.04 |
| Support Level | $19.81 | $15.47 |
| Resistance Level | $22.71 | $21.75 |
| Average True Range (ATR) | 0.91 | 1.10 |
| MACD | -0.11 | -0.05 |
| Stochastic Oscillator | 46.63 | 31.76 |
Permian Basin Royalty Trust is an express trust. The company's underlying properties include Waddell Ranch Properties in which the trust holds mineral interest as well as royalty interests in mature producing oil fields, such as Yates, Wasson, Sand Hills, East Texas, Kelly-Snyder, Panhandle Regular, N. Cowden, Todd, Keystone, Kermit, McElroy, Howard-Glasscock, Seminole, and others across Texas. The company earns the majority of its revenue in the form of royalties received through its properties.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.